BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25448457)

  • 1. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients.
    Shim SH; Lee SJ; Kim SO; Kim SN; Kim DY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2015 Jan; 136(1):30-6. PubMed ID: 25448457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results.
    Alessi A; Martinelli F; Padovano B; Serafini G; Lorusso D; Lorenzoni A; Ditto A; Lecce F; Mira M; Donfrancesco C; Raspagliesi F; Crippa F
    Tumori; 2016; 102(1):103-7. PubMed ID: 26350201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study.
    Risum S; Høgdall C; Loft A; Berthelsen AK; Høgdall E; Nedergaard L; Lundvall L; Engelholm SA
    Gynecol Oncol; 2008 Feb; 108(2):265-70. PubMed ID: 18055006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
    Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
    J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer.
    Fruscio R; Sina F; Dolci C; Signorelli M; Crivellaro C; Dell'Anna T; Cuzzocrea M; Guerra L; Milani R; Messa C
    Gynecol Oncol; 2013 Dec; 131(3):689-93. PubMed ID: 24076062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of complex surgical procedures, patterns of tumor spread, and CA-125 predicts a risk of incomplete cytoreduction: a Korean Gynecologic Oncology Group study (KGOG-3022).
    Jung DC; Kang S; Kim SC; Kim JW; Nam JH; Ryu SY; Seong SJ; Kim BG
    Gynecol Oncol; 2013 Nov; 131(2):336-40. PubMed ID: 23954903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
    Eskander RN; Kauderer J; Tewari KS; Mannel RS; Bristow RE; O'Malley DM; Rubin SC; Glaser GE; Hamilton CA; Fujiwara K; Huh WK; Ueland F; Stephan JM; Burger RA
    Gynecol Oncol; 2018 Jun; 149(3):525-530. PubMed ID: 29550184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
    Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P
    Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer.
    Fanfani F; Monterossi G; Fagotti A; Gallotta V; Costantini B; Vizzielli G; Petrillo M; Carbone MV; Scambia G
    Ann Surg Oncol; 2015 Feb; 22(2):649-54. PubMed ID: 25155399
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Liu S; Feng Z; Wen H; Jiang Z; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X
    Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
    Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Iyer RB; Zhou Q; Iasonos A; Denesopolis J; Zivanovic O; Long Roche KC; Sonoda Y; Coleman RL; Abu-Rustum NR; Hricak H; Chi DS
    Gynecol Oncol; 2017 Apr; 145(1):27-31. PubMed ID: 28209497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
    Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
    Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
    Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
    Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
    Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.
    Hynninen J; Kemppainen J; Lavonius M; Virtanen J; Matomäki J; Oksa S; Carpén O; Grénman S; Seppänen M; Auranen A
    Gynecol Oncol; 2013 Nov; 131(2):389-94. PubMed ID: 23994535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept.
    Petrillo M; Vizzielli G; Fanfani F; Gallotta V; Cosentino F; Chiantera V; Legge F; Carbone V; Scambia G; Fagotti A
    Gynecol Oncol; 2015 Oct; 139(1):5-9. PubMed ID: 26196319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer.
    Paik ES; Lee YY; Kim TJ; Choi CH; Lee JW; Kim BG; Bae DS
    J Gynecol Oncol; 2016 May; 27(3):e24. PubMed ID: 27029745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer.
    Son JH; Chang K; Kong TW; Paek J; Chang SJ; Ryu HS
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1294-1301. PubMed ID: 29683235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer.
    Barlin JN; Yu C; Hill EK; Zivanovic O; Kolev V; Levine DA; Sonoda Y; Abu-Rustum NR; Huh J; Barakat RR; Kattan MW; Chi DS
    Gynecol Oncol; 2012 Apr; 125(1):25-30. PubMed ID: 22155261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
    Risum S; Loft A; Engelholm SA; Høgdall E; Berthelsen AK; Nedergaard L; Lundvall L; Høgdall C
    Int J Gynecol Cancer; 2012 Sep; 22(7):1163-9. PubMed ID: 22810969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.